Baxter International (BAX) is poised for growth, given the demand for its medically essential products, coupled with transformational actions. However, inflationary pressure remains a concern.Shares of this Zacks Rank #3 (Hold) company have gained 10.8% year to date compared with the industry's 5.3% growth. The S&P 500 Index has increased 9.4% in the same time frame.BAX, with a market capitalization of $21.46 billion, is a global medical technology company providing items such as kidney-dialysis equipment, ...

Baxter International Inc. (BAX) recently received the FDA’s 510(k) clearance for its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software. Adding LVP modality to the Novum IQ Infusion Platform, which includes Baxter’s syringe infusion pump (SYR) with Dose IQ Safety Software, powered by the IQ Enterprise Connectivity Suite, is expected to enable clinicians to utilize a single, integrated system across a variety of patient care settings.Baxter expects to expand the platform in the future via ...

monsitj In this article, I will outline why I think Baxter International Inc. (NYSE:BAX) is a buy. BAX is a member of the health care industry and sells health care equipment. While not a factor in my analysis, BAX is expected to see double-digit earnings per share growth over the next three years, which is attractive. My technical analysis will focus on price action, momentum, volume, and relative strength using a weekly time frame. I will also mention the importance of risk management in this article, ...

Core Insights - Spectral Medical Inc. has achieved a significant milestone by reaching its Interim Enrollment target of 90 patients in the TIGRIS trial, which is crucial for the development of its product PMX for treating septic shock [1][2] - Baxter International has the option to make a second milestone payment to Spectral to maintain its exclusive distribution rights for PMX following this enrollment milestone [1] Company Overview - Spectral is a late-stage theranostic company focused on advancing therapeutic options for sepsis and septic shock, with its product Toraymyxin™ (PMX) being a therapeutic hemoperfusion device that removes endotoxin from the bloodstream [3] - PMX is already approved for therapeutic use in Japan and Europe, having been safely and effectively used on over 340,000 patients [3] - The company has exclusive development and commercial rights for PMX in the U.S. since March 2009 and signed an exclusive distribution agreement for Canada in November 2010 [3] TIGRIS Trial Details - The TIGRIS trial is a confirmatory study comparing PMX in addition to standard care against standard care alone, designed as a 2:1 randomized trial involving 150 patients [4] - The trial employs Bayesian statistics to analyze the results, which is a novel approach in sepsis trials [4]

Core Viewpoint - Baxter International Inc. has declared a quarterly cash dividend of $0.29 per share, indicating a strong commitment to returning value to shareholders [1]. Group 1: Dividend Announcement - The quarterly cash dividend of $0.29 per share is payable on April 1, 2024, to stockholders of record as of March 1, 2024 [1]. - The indicated annual dividend rate is $1.16 per share of common stock [1]. Group 2: Company Overview - Baxter operates in the healthcare sector, providing a wide range of products including diagnostic, critical care, kidney care, nutrition, hospital, and surgical products [2]. - The company has been in operation for over 90 years, focusing on innovations that save and sustain lives [2]. - Baxter's products and digital health solutions are available in more than 100 countries, highlighting its global reach and commitment to advancing healthcare innovations [2].

Core Viewpoint - Baxter International Inc. reported better-than-expected adjusted earnings per share (EPS) for the fourth quarter of 2023, but the stock experienced a decline in pre-market trading despite the positive results [1][2]. Financial Performance - Adjusted EPS from continuing operations was 88 cents, exceeding the Zacks Consensus Estimate of 86 cents by 2.3% and improving 13% year-over-year [1]. - Total revenues from continued operations reached $3.89 billion, reflecting a 4% increase on a reported basis and 3% at constant currency, surpassing the Zacks Consensus Estimate by 2.4% [2]. - For the full year 2023, Baxter recorded total revenues of $14.81 billion, up 2% year-over-year, while adjusted EPS from continuing operations was $2.60, down 14% from the previous year [9]. Segment Performance - The Medical Products & Therapies segment generated sales of $1.32 billion, up 6% year-over-year [4]. - Infusion Therapies and Technologies sales totaled $1.04 billion, increasing by 5% year-over-year, while Advanced Surgery sales reached $278 million, up 7% [5]. - The Healthcare Systems and Technologies segment reported sales of $795 million, an 8% increase year-over-year [6]. - The Pharmaceuticals segment's sales were $596 million, up 8% year-over-year [6]. - The Kidney Care segment saw total sales of $1.16 billion, down 1% year-over-year, with Chronic Therapies sales at $950 million, down 2% [7]. Margin Analysis - Adjusted gross profit for the fourth quarter was $1.63 billion, a 5.7% increase year-over-year, with a gross margin improvement of 80 basis points to 42% [8]. - Adjusted operating income from continuing operations was $449 million, up 13% year-over-year, with an operating margin improvement of 90 basis points to 11.6% [8]. Future Guidance - For Q1 2024, Baxter anticipates sales growth of approximately 1% on a reported basis, with adjusted EPS expected between 59 cents and 62 cents [10]. - For the full year 2024, sales growth is projected to be nearly 2% on a reported basis, with adjusted EPS expected in the range of $2.85 to $2.95 [10].

FO URT H-Q UA RT ER 2023 EA RNI NGS Baxter International Inc. February 8, 2024 FORWA R D- LOOKING STAT EM ENT S This pr ...

Start Time: 08:30 January 1, 0000 9:32 AM ET Baxter International Inc. (NYSE:BAX) Q4 2023 Earnings Conference Call February 08, 2024, 08:30 AM ET Executives Clare Trachtman - VP, IR Jose Almeida - Chairman, President and CEO Joel Grade - EVP and CFO Analysts Travis Steed - Bank of America Securities Matt Miksic - Barclays Vijay Kumar - Evercore ISI Pito Chickering - Deutsche Bank Securities Matt Taylor - Jefferies Danielle Antalffy - UBS Operator Good morning, ladies and gentlemen, and welcome to Baxter Int ...

Baxter International (BAX) reported $3.89 billion in revenue for the quarter ended December 2023, representing a year-over-year decline of 0.1%. EPS of $0.88 for the same period compares to $0.88 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $3.8 billion, representing a surprise of +2.28%. The company delivered an EPS surprise of +2.33%, with the consensus EPS estimate being $0.86.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings - ...

Company Performance - Baxter International reported quarterly earnings of $0.88 per share, exceeding the Zacks Consensus Estimate of $0.86 per share, and matching the earnings from a year ago [1] - The company achieved revenues of $3.89 billion for the quarter ended December 2023, surpassing the Zacks Consensus Estimate by 2.28%, with revenues unchanged from the previous year [1] - Over the last four quarters, Baxter has surpassed consensus EPS estimates three times and has topped consensus revenue estimates three times as well [1] Market Performance - Baxter shares have increased approximately 1.9% since the beginning of the year, compared to the S&P 500's gain of 4.7% [2] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.63 on revenues of $3.61 billion, and for the current fiscal year, it is $2.93 on revenues of $15.19 billion [4] - The estimate revisions trend for Baxter is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [3] Industry Context - The Medical - Products industry, to which Baxter belongs, is currently in the bottom 33% of over 250 Zacks industries, suggesting potential challenges ahead [4] - The performance of Baxter's stock may be influenced by the overall outlook for the industry [4]